<mets:mets OBJID="eprint_95289" LABEL="Eprints Item" xsi:schemaLocation="http://www.loc.gov/METS/ http://www.loc.gov/standards/mets/mets.xsd http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-3.xsd" xmlns:mods="http://www.loc.gov/mods/v3" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mets="http://www.loc.gov/METS/"><mets:metsHdr CREATEDATE="2026-11-07T04:40:02Z"><mets:agent TYPE="ORGANIZATION" ROLE="CUSTODIAN"><mets:name>Arxiv Universal Publishings</mets:name></mets:agent></mets:metsHdr><mets:dmdSec ID="DMD_eprint_95289_mods"><mets:mdWrap MDTYPE="MODS"><mets:xmlData><mods:titleInfo><mods:title>IMMUNOMODULATORY THERAPIES FOR PREVENTING THROMBOSIS IN IMMUNE-MEDIATED MICROVASCULAR THROMBOTIC DISEASES</mods:title></mods:titleInfo><mods:name type="personal"><mods:namePart type="given">Z.Ch</mods:namePart><mods:namePart type="family">Kurbanova</mods:namePart><mods:role><mods:roleTerm type="text">author</mods:roleTerm></mods:role></mods:name><mods:name type="personal"><mods:namePart type="given">S.A</mods:namePart><mods:namePart type="family">Babadjanov</mods:namePart><mods:role><mods:roleTerm type="text">author</mods:roleTerm></mods:role></mods:name><mods:name type="personal"><mods:namePart type="given">U.A</mods:namePart><mods:namePart type="family">Begmatova</mods:namePart><mods:role><mods:roleTerm type="text">author</mods:roleTerm></mods:role></mods:name><mods:abstract>Immune-mediated microvascular thrombotic diseases (IMTD), such as systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS), increase the risk of microvascular thrombosis due to chronic inflammation and autoimmune activity. While anticoagulant therapy is crucial for managing thrombotic events, immunomodulatory therapies may provide additional benefits by targeting underlying immune dysfunction. This study evaluated the efficacy of biologic agents (IL-6 antagonists, TNF inhibitors, rituximab) and complement inhibitors in reducing thrombotic risk over 12 months in 50 patients with IMTD (aged 18–65). Inflammatory markers (CRP, IL-6) and thrombotic indicators (D-dimer, fibrinogen) were elevated at baseline and significantly decreased post-therapy (p&amp;lt;0.01). Rituximab reduced antibody levels by 30% in SLE patients (p&amp;lt;0.05), with a 15% reduction in thrombotic events. IL-6 antagonists decreased inflammation and thrombotic risk by 20% (p=0.03). However, bleeding risk was observed in 8% of patients. These findings highlight the potential of immunomodulatory therapies as adjuncts to anticoagulants, though larger trials are needed.</mods:abstract><mods:originInfo><mods:dateIssued encoding="iso8601">2025-05-17</mods:dateIssued></mods:originInfo><mods:genre>Maqola</mods:genre></mets:xmlData></mets:mdWrap></mets:dmdSec><mets:amdSec ID="TMD_eprint_95289"><mets:rightsMD ID="rights_eprint_95289_mods"><mets:mdWrap MDTYPE="MODS"><mets:xmlData><mods:useAndReproduction>
<p xmlns="http://www.w3.org/1999/xhtml"><strong>For work being deposited by its own author:</strong>
In self-archiving this collection of files and associated bibliographic
metadata, I grant Arxiv Universal Publishings the right to store
them and to make them permanently available publicly for free on-line.
I declare that this material is my own intellectual property and I
understand that Arxiv Universal Publishings does not assume any
responsibility if there is any breach of copyright in distributing these
files or metadata. (All authors are urged to prominently assert their
copyright on the title page of their work.)</p>

<p xmlns="http://www.w3.org/1999/xhtml"><strong>For work being deposited by someone other than its
author:</strong> I hereby declare that the collection of files and
associated bibliographic metadata that I am archiving at
Arxiv Universal Publishings is in the public domain. If this is
not the case, I accept full responsibility for any breach of copyright
that distributing these files or metadata may entail.</p>

<p xmlns="http://www.w3.org/1999/xhtml">Clicking on the <em>Deposit Item Now</em> button indicates your agreement to these
terms.</p>
    </mods:useAndReproduction></mets:xmlData></mets:mdWrap></mets:rightsMD></mets:amdSec><mets:fileSec><mets:fileGrp USE="reference"><mets:file OWNERID="https://arxiv.universalpublishings.com/id/eprint/95289/1/69-72_3_.pdf" ID="eprint_95289_16916_1" SIZE="455590" MIMETYPE="application/pdf"><mets:FLocat xlink:type="simple" xlink:href="https://arxiv.universalpublishings.com/id/eprint/95289/1/69-72_3_.pdf" LOCTYPE="URL"></mets:FLocat></mets:file></mets:fileGrp></mets:fileSec><mets:structMap><mets:div ADMID="TMD_eprint_95289" DMDID="DMD_eprint_95289_mods"><mets:fptr FILEID="eprint_95289_document_16916_1"></mets:fptr></mets:div></mets:structMap></mets:mets>